77:
research in the international context. Over the next several years they came to focus the mission of the foundation on heart disease and stroke, awarding $ 30M in single investigator grants in 1999 and 2001. In 2003, the foundation created its signature program, the
Transatlantic Networks of Excellence in Cardiovascular Research, to support internationally collaborative research in heart disease and stroke. The Initial grants were awarded to research investigators from North American and Europe, the two continents where the Leducqs had lived and worked. The program, now under the name International Networks of Excellence, has been expanded to be open to researchers worldwide.
140:, has focused on three major activities. First is the identification of a biomarker for acute rheumatic fever which, notwithstanding its importance in the eventual development of rheumatic heart disease, remains difficult to diagnose. Second are efforts to develop a vaccine against the Group A streptococcus infection, which is causally implicated in rheumatic heart disease. The third activity is focused on development of novel prosthetic heart valve technologies that might provide durable and non-thrombogenic solutions for individuals already affected by rheumatic heart disease, and may be used at scale in areas where rheumatic heart disease is endemic.
156:
made under this program to be used either for additional
Broadview investments or to provide further funding for Leducq Foundation programs. In 2018, The Leducq Charitable Trust developed a later-stage investment program, Longview Healthcare Ventures, which concentrates on follow-on investments in select Broadview program companies that are poised to achieve significant value-creating milestones with their next financing round. Longview focuses on clinical-stage companies, Series B – Series C, as a complement to Broadview’s continued dedication to Seed and Series A financings.
125:. Recently, Leducq researchers have played prominent roles in developing the use of stem cells for modeling human diseases, understanding the role of inflammation in atherosclerosis, advancing knowledge of renal physiology in hypertension, shedding insights into mechanisms of intracellular cholesterol transport, and elucidating mechanisms of cerebral small vessel disease. Leducq investigators have also identified Calcium Calmodulin Kinase II as a critical node in signaling pathways in atrial fibrillation and heart failure, provided new models of
52:
Leducq has distributed or committed more than $ 500 million to the INE program, awarding an average of four INE grants per year, with a current award of $ 8 million each over a five-year term. The program requires that the network leaders be from different continents, and participation is open to investigators worldwide. The Leducq
Foundation Scientific Advisory Committee (SAC) is responsible for evaluating the scientific merit of applications to the
149:
Inc., a Boston, Massachusetts based venture philanthropic program dedicated to accelerating the development of innovative technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investment. The Leducq
Corporation, also located in Boston, MA, provides administrative services to the Leducq organization’s grant-making entities.
44:, both part of a Boston, Massachusetts based venture philanthropic program dedicated to accelerating the development of innovative technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments. Leducq’s philanthropic mission is to improve human health through international efforts to combat
610:
Purohit, A.; Rokita, A. G.; Guan, X.; Chen, B.; Koval, O. M.; Voigt, N.; Neef, S.; Sowa, T.; Gao, Z.; Luczak, E. D.; Stefansdottir, H.; Behunin, A. C.; Li, N.; El-Accaoui, R. N.; Yang, B.; Swaminathan, P. D.; Weiss, R. M.; Wehrens, X. H.; Song, L. S.; Dobrev, D.; Maier, L. S.; Anderson, M. E. (2013).
346:
Fidler, T. P.; Xue, C.; Yalcinkaya, M.; Hardaway, B.; Abramowicz, S.; Xiao, T.; Liu, W.; Thomas, D. G.; Hajebrahimi, M. A.; Pircher, J.; Silvestre-Roig, C.; Kotini, A. G.; Luchsinger, L. L.; Wei, Y.; Westerterp, M.; Snoeck, H. W.; Papapetrou, E. P.; Schulz, C.; Massberg, S.; Soehnlein, O.; Ebert, B.;
155:
was created by the Leducq
Charitable Trust in 2009 to enable the trust to provide seed and early-stage funding to companies developing innovative technologies for the diagnosis and treatment of cardiovascular disease and stroke. Broadview is mission, not-for-profit driven, with any investment return
148:
The Leducq organization includes the Leducq
Charitable Trust and the Leducq Foundation, both based in the Bahamas, the United States-based Leducq Foundation for Cardiovascular Research, a not-for-profit private foundation under section 501(c)(3) of the Internal Revenue Code, and Broadview Ventures,
451:
Sandhu, J.; Li, S.; Fairall, L.; Pfisterer, S. G.; Gurnett, J. E.; Xiao, X.; Weston, T. A.; Vashi, D.; Ferrari, A.; Orozco, J. L.; Hartman, C. L.; Strugatsky, D.; Lee, S. D.; He, C.; Hong, C.; Jiang, H.; Bentolila, L. A.; Gatta, A. T.; Levine, T. P.; Ferng, A.; Lee, R.; Ford, D. A.; Young, S. G.;
51:
The Leducq
Foundation’s principal grant program, the International Networks of Excellence (INE) for Cardiovascular and Neurovascular Research, promotes internationally collaborative basic and translational research to advance the knowledge of cardiovascular and neurovascular disease. Since 2003,
76:
Jean Leducq was a French entrepreneur who over the course of 50 years built a successful international linen supply business in Europe (ELIS) and North
America (RUS). With his wife Sylviane Leducq, he created the Paris-based Fondation Leducq in November 1996 for the purpose of supporting medical
80:
After Jean Leducq died in 2002, Sylviane Leducq served as
President of the Board of Directors until her death in 2013. She oversaw the implementation of the International Networks of Excellence Program (INE), and the development of the venture philanthropy program Broadview Ventures. In 2009,
660:
Sauls, K.; De
Vlaming, A.; Harris, B. S.; Williams, K.; Wessels, A.; Levine, R. A.; Slaugenhaupt, S. A.; Goodwin, R. L.; Pavone, L. M.; Merot, J.; Schott, J. J.; Le Tourneau, T.; Dix, T.; Jesinkey, S.; Feng, Y.; Walsh, C.; Zhou, B.; Baldwin, S.; Markwald, R. R.; Norris, R. A. (2012).
67:
Beginning in 2021 the Leducq Foundation has made an ongoing commitment to supporting research in rheumatic heart disease, a significant unmet medical need, particularly in low- and middle-income countries.
501:
Dabertrand, Fabrice; Krøigaard, Christel; Bonev, Adrian D.; Cognat, Emmanuel; Dalsgaard, Thomas; Domenga-Denier, Valérie; Hill-Eubanks, David C.; Brayden, Joseph E.; Joutel, Anne; Nelson, Mark T. (2015).
823:
828:
818:
225:
238:
Wu, Joseph C.; Garg, Priyanka; Yoshida, Yoshinori; Yamanaka, Shinya; Gepstein, Lior; Hulot, Jean-Sébastien; Knollmann, Björn C.; Schwartz, Peter J. (2019).
813:
137:
164:
504:"Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease"
53:
93:
Research projects currently funded by the Foundation span the major areas of cardiovascular and neurovascular disease, including
760:
122:
94:
118:
114:
45:
454:"Aster Proteins Facilitate Nonvesicular Plasma Membrane to ER Cholesterol Transport in Mammalian Cells"
515:
360:
133:
126:
433:
279:
765:
741:
692:
642:
592:
543:
483:
425:
386:
328:
271:
207:
731:
723:
682:
674:
632:
624:
582:
574:
533:
523:
473:
465:
417:
376:
368:
318:
310:
261:
251:
197:
82:
160:
61:
519:
364:
266:
239:
736:
711:
687:
662:
637:
612:
587:
562:
538:
503:
478:
453:
381:
348:
323:
298:
132:
The Leducq rheumatic heart disease initiative, guided by expert advisory committees on
628:
159:
The bequest from the Leducq family to the charitable Leducq organization includes the
56:. It is composed equally of North American and European members, who are experts in
807:
437:
283:
98:
110:
40:
256:
202:
185:
727:
578:
508:
Proceedings of the National Academy of Sciences of the United States of America
469:
372:
663:"Developmental basis for filamin-A-associated myxomatous mitral valve disease"
314:
106:
57:
299:"Transcriptional and epigenetic regulation of macrophages in atherosclerosis"
528:
405:
349:"The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis"
34:
745:
696:
646:
596:
547:
487:
429:
390:
332:
275:
211:
421:
678:
240:"Towards Precision Medicine with Human iPSCs for Cardiac Channelopathies"
32:, a not-for-profit private foundation under the 501(c)(3) tax code, and
347:
Levine, R. L.; Reilly, M. P.; Libby, P.; Wang, N.; Tall, A. R. (2021).
102:
788:
85:
in recognition of her generosity and leadership of the foundation.
28:
22:
297:
Kuznetsova, T.; Prange KHM; Glass, C. K.; de Winther MPJ (2020).
152:
129:, and implicated inflammation in post-stroke cognitive decline.
793:
167:, which supports the foundation’s philanthropic mission.
798:
783:
26:, both based in the Bahamas, the United States-based
563:"CaMKII in myocardial hypertrophy and heart failure"
824:
Medical and health foundations in the United States
561:Anderson, M. E.; Brown, J. H.; Bers, D. M. (2011).
712:"Immunological mechanisms in post-stroke dementia"
226:Légion d’Honneur : la promotion du Nouvel an
406:"Insights into Salt Handling and Blood Pressure"
613:"Oxidized CaMKII Triggers Atrial Fibrillation"
452:Ikonen, E.; Schwabe JWR; Tontonoz, P. (2018).
829:Non-profit organisations based in the Bahamas
29:Leducq Foundation for Cardiovascular Research
8:
567:Journal of Molecular and Cellular Cardiology
184:Tancredi, David; Braunwald, Eugene (2014).
735:
686:
636:
586:
537:
527:
477:
380:
322:
265:
255:
201:
710:Doyle, K. P.; Buckwalter, M. S. (2020).
176:
16:The Leducq organization comprises the
819:Health charities in the United States
7:
404:Ellison, D. H.; Welling, P. (2021).
410:The New England Journal of Medicine
14:
629:10.1161/CIRCULATIONAHA.113.003313
105:, cerebral small vessel disease,
81:Sylviane Leducq was awarded the
814:Biomedical research foundations
759:Garbee, Kevin (3 August 2008).
64:, and neurovascular medicine.
1:
257:10.1161/CIRCRESAHA.119.315209
203:10.1161/CIRCRESAHA.115.304626
761:"Reawakening Napa's spirits"
728:10.1097/WCO.0000000000000783
716:Current Opinion in Neurology
41:Longview Healthcare Ventures
579:10.1016/j.yjmcc.2011.01.012
224:Ch. D. (January 2, 2009). "
845:
470:10.1016/j.cell.2018.08.033
373:10.1038/s41586-021-03341-5
303:Nature Reviews. Cardiology
138:rheumatic fever biomarkers
315:10.1038/s41569-019-0265-3
228:". Le Figaro, in French.
123:congenital heart disease
35:Broadview Ventures, Inc.
667:Cardiovascular Research
529:10.1073/pnas.1420765112
161:Napa Valley, California
95:coronary artery disease
18:Leducq Charitable Trust
119:pulmonary hypertension
115:valvular heart disease
422:10.1056/NEJMra2030212
244:Circulation Research
190:Circulation Research
127:mitral valve disease
48:disease and stroke.
520:2015PNAS..112E.796D
365:2021Natur.592..296F
134:vaccine development
107:cardiac arrhythmias
789:Broadview Ventures
679:10.1093/cvr/cvs238
464:(2): 514–529.e20.
186:"Fondation Leducq"
153:Broadview Ventures
784:Leducq Foundation
766:Los Angeles Times
623:(16): 1748–1757.
416:(21): 1981–1993.
359:(7853): 296–301.
23:Leducq Foundation
836:
771:
770:
756:
750:
749:
739:
707:
701:
700:
690:
657:
651:
650:
640:
607:
601:
600:
590:
558:
552:
551:
541:
531:
498:
492:
491:
481:
448:
442:
441:
401:
395:
394:
384:
343:
337:
336:
326:
294:
288:
287:
269:
259:
235:
229:
222:
216:
215:
205:
181:
83:Légion d’Honneur
844:
843:
839:
838:
837:
835:
834:
833:
804:
803:
780:
775:
774:
758:
757:
753:
709:
708:
704:
659:
658:
654:
609:
608:
604:
560:
559:
555:
514:(7): E796–805.
500:
499:
495:
450:
449:
445:
403:
402:
398:
345:
344:
340:
296:
295:
291:
237:
236:
232:
223:
219:
183:
182:
178:
173:
146:
91:
74:
62:cardiac surgery
12:
11:
5:
842:
840:
832:
831:
826:
821:
816:
806:
805:
802:
801:
796:
791:
786:
779:
778:External links
776:
773:
772:
751:
702:
673:(1): 109–119.
652:
602:
573:(4): 468–473.
553:
493:
443:
396:
338:
309:(4): 216–228.
289:
250:(6): 653–658.
230:
217:
196:(4): 419–422.
175:
174:
172:
169:
145:
142:
90:
87:
73:
70:
46:cardiovascular
13:
10:
9:
6:
4:
3:
2:
841:
830:
827:
825:
822:
820:
817:
815:
812:
811:
809:
800:
797:
795:
794:Ehlers Estate
792:
790:
787:
785:
782:
781:
777:
768:
767:
762:
755:
752:
747:
743:
738:
733:
729:
725:
721:
717:
713:
706:
703:
698:
694:
689:
684:
680:
676:
672:
668:
664:
656:
653:
648:
644:
639:
634:
630:
626:
622:
618:
614:
606:
603:
598:
594:
589:
584:
580:
576:
572:
568:
564:
557:
554:
549:
545:
540:
535:
530:
525:
521:
517:
513:
509:
505:
497:
494:
489:
485:
480:
475:
471:
467:
463:
459:
455:
447:
444:
439:
435:
431:
427:
423:
419:
415:
411:
407:
400:
397:
392:
388:
383:
378:
374:
370:
366:
362:
358:
354:
350:
342:
339:
334:
330:
325:
320:
316:
312:
308:
304:
300:
293:
290:
285:
281:
277:
273:
268:
263:
258:
253:
249:
245:
241:
234:
231:
227:
221:
218:
213:
209:
204:
199:
195:
191:
187:
180:
177:
170:
168:
166:
165:Ehlers Estate
162:
157:
154:
150:
143:
141:
139:
135:
130:
128:
124:
120:
116:
112:
108:
104:
100:
99:heart failure
96:
88:
86:
84:
78:
71:
69:
65:
63:
59:
55:
49:
47:
43:
42:
37:
36:
31:
30:
25:
24:
19:
764:
754:
722:(1): 30–36.
719:
715:
705:
670:
666:
655:
620:
616:
605:
570:
566:
556:
511:
507:
496:
461:
457:
446:
413:
409:
399:
356:
352:
341:
306:
302:
292:
247:
243:
233:
220:
193:
189:
179:
163:, vineyard,
158:
151:
147:
131:
111:hypertension
92:
79:
75:
66:
50:
39:
33:
27:
21:
17:
15:
617:Circulation
54:INE program
808:Categories
171:References
58:cardiology
438:244346126
284:201674231
144:Structure
746:31789707
697:22843703
647:24030498
597:21276796
548:25646445
488:30220461
430:34788509
391:33731931
333:31578516
276:31465267
267:10765953
212:25081133
737:7251986
688:3444235
638:3876034
588:3158288
539:4343103
516:Bibcode
479:6469685
382:8038646
361:Bibcode
324:7770754
89:Science
72:History
744:
734:
695:
685:
645:
635:
595:
585:
546:
536:
486:
476:
436:
428:
389:
379:
353:Nature
331:
321:
282:
274:
264:
210:
136:, and
121:, and
103:stroke
434:S2CID
280:S2CID
799:ELIS
742:PMID
693:PMID
643:PMID
593:PMID
544:PMID
484:PMID
458:Cell
426:PMID
387:PMID
329:PMID
272:PMID
208:PMID
38:and
20:and
732:PMC
724:doi
683:PMC
675:doi
633:PMC
625:doi
621:128
583:PMC
575:doi
534:PMC
524:doi
512:112
474:PMC
466:doi
462:175
418:doi
414:385
377:PMC
369:doi
357:592
319:PMC
311:doi
262:PMC
252:doi
248:125
198:doi
194:115
113:,
810::
763:.
740:.
730:.
720:33
718:.
714:.
691:.
681:.
671:96
669:.
665:.
641:.
631:.
619:.
615:.
591:.
581:.
571:51
569:.
565:.
542:.
532:.
522:.
510:.
506:.
482:.
472:.
460:.
456:.
432:.
424:.
412:.
408:.
385:.
375:.
367:.
355:.
351:.
327:.
317:.
307:17
305:.
301:.
278:.
270:.
260:.
246:.
242:.
206:.
192:.
188:.
117:,
109:,
101:,
97:,
60:,
769:.
748:.
726::
699:.
677::
649:.
627::
599:.
577::
550:.
526::
518::
490:.
468::
440:.
420::
393:.
371::
363::
335:.
313::
286:.
254::
214:.
200::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.